scPharmaceuticals Inc. DEF 14A: Executive Compensation Details
| Field | Detail |
|---|---|
| Company | Scpharmaceuticals Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
TL;DR
scPharmaceuticals Inc. DEF 14A out: exec comp details for FY24, equity awards, option values.
AI Summary
scPharmaceuticals Inc. filed a DEF 14A on April 21, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted and vested, changes in the fair value of options and SARs, and year-end fair values of outstanding equity awards for both executive (PEO) and non-executive (Non-PEO) members. Specific dollar amounts and dates related to these compensation elements are provided within the detailed tables.
Why It Matters
This filing provides transparency into how scPharmaceuticals Inc. compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: medium — DEF 14A filings often contain detailed executive compensation information, which can be complex and subject to interpretation, potentially impacting stock valuation.
Key Numbers
- FY24 — Fiscal Year (Executive compensation data pertains to this period.)
- FY23 — Fiscal Year (Executive compensation data pertains to this period.)
- FY22 — Fiscal Year (Executive compensation data pertains to this period.)
Key Players & Entities
- scPharmaceuticals Inc. (company) — Filer
- 20250421 (date) — Filing Date
- 20250603 (date) — Period of Report
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the total reported compensation for the Named Executive Officers (NEOs) for the fiscal year ending December 31, 2024?
The filing indicates that detailed compensation information for NEOs for the fiscal year ending December 31, 2024, is presented in the Summary Compensation Table, but specific dollar amounts are not provided in the excerpt.
How did the fair value of options and SARs granted in prior years change during the fiscal year 2024?
The filing includes data points for 'ChangeInFairValueOfOptionsAndSARsModifiedDuringFiscalYearMember' for PEO and Non-PEO members for the period 2024-01-01 to 2024-12-31, indicating changes occurred.
What was the year-end fair value of equity awards granted in the covered year that were outstanding and unvested as of December 31, 2023?
The filing references 'ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' for the period 2023-01-01 to 2023-12-31, suggesting this information is available.
What is the business address of scPharmaceuticals Inc.?
The business address is 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA 01803.
What is the SIC code for scPharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 regarding scPharmaceuticals Inc..